Ruan Qiang, Yang Xian-Zi, Zhu Lin, He Qing-Jun, Zhu Si-Yu, Wen Yue-Feng, Ma Lei
The First Affiliated Hospital of Jinan University, the First Clinical Medical College of Jinan University, Guangzhou, 510630, China; Department of the second area of Gastrointestinal Surgery, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Department of Medical Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, 510095, China.
Pathol Res Pract. 2021 Aug;224:153506. doi: 10.1016/j.prp.2021.153506. Epub 2021 May 30.
A recent study has reported that miR-3650 expression was significant reduced in hepatocellular carcinoma and predicted poor prognosis. However, the role of miR-3650 in nasopharyngeal carcinoma (NPC) remains indefinite.
Total 140 cases of NPCs were included in this study. The expression of miR-3650 was determined in NPC tissues and adjacent nontumor tissues using qRT-PCR. Then the relationship between miR-3650 expression and clinicopathological features as well as survival were analyzed.
The expression of miR-3650 was significant higher in NPC tissues than that in adjacent nontumor tissues (P < 0.001). High expression of miR-3650 was significant correlated with tumor progression and distant metastasis of NPC patients. And patients with high miR-3650 expression have much worse 5-year overall survival (OS) and 5-year progression-free survival (PFS) than those with low expression (all P < 0.0001). Furthermore, Cox regression analysis showed that miR-3650 was an independent risk predictor for OS and PFS in NPC patients (all P = 0.000).
Our results demonstrated for the first time that miR-3650 was markedly upregulated in NPC tissues and positively associated with tumor progression and poor survival, suggesting that miR-3650 may be a potential novel prognostic biomarker and therapeutic target for NPC patients.
最近一项研究报道,miR-3650在肝细胞癌中的表达显著降低,并预示着预后不良。然而,miR-3650在鼻咽癌(NPC)中的作用仍不明确。
本研究共纳入140例NPC患者。采用qRT-PCR检测NPC组织及癌旁非肿瘤组织中miR-3650的表达。然后分析miR-3650表达与临床病理特征及生存率之间的关系。
NPC组织中miR-3650的表达显著高于癌旁非肿瘤组织(P < 0.001)。miR-3650的高表达与NPC患者的肿瘤进展和远处转移显著相关。miR-3650高表达的患者5年总生存率(OS)和5年无进展生存率(PFS)比低表达患者差得多(所有P < 0.0001)。此外,Cox回归分析显示,miR-3650是NPC患者OS和PFS的独立风险预测因子(所有P = 0.000)。
我们的结果首次表明,miR-3650在NPC组织中显著上调,与肿瘤进展和不良生存呈正相关,提示miR-3650可能是NPC患者潜在的新型预后生物标志物和治疗靶点。